Compare ALXO & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALXO | ZTEK |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 78.2M |
| IPO Year | 2020 | N/A |
| Metric | ALXO | ZTEK |
|---|---|---|
| Price | $1.16 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | ★ 210.9K | 87.1K |
| Earning Date | 03-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $657,134.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2225.73 |
| 52 Week Low | $0.40 | $0.62 |
| 52 Week High | $2.27 | $1.84 |
| Indicator | ALXO | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 55.39 |
| Support Level | $1.07 | $0.85 |
| Resistance Level | $1.56 | $1.09 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 21.43 | 47.22 |
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.